Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker

Trial Profile

Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2018 Planned End Date changed from 31 Mar 2020 to 31 Dec 2018.
    • 29 Sep 2018 Status changed from suspended to discontinued.
    • 11 May 2018 Planned End Date changed from 1 Mar 2016 to 31 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top